Coverage: The Meridian legal market record (editorial).
The licensed territory is stated only as 'the MENA region'. No African country is individually named in the release, so the African connection rests on the regional definition of MENA and on Julphar's stated MENA footprint. Recorded as a regional-scope licence, not a confirmed African-market licence.
| Record ID | TX-AFR-2025-0009 |
|---|---|
| Record type | Commercial IP transaction |
| Transaction type | Patent licence, Technology transfer, Exclusive licence, In-licensing |
| IP rights | patent, know-how, regulatory data |
| Status | Signed |
| Qualifying date | 2025-03-05 |
| Sector | Life sciences · Pharmaceuticals – biosimilars |
| African markets | Multi-jurisdictional |
| Licensed territory | MENA region as stated in the parties' release; no country list and no African country named. |
| Disclosed value | Not disclosed in the sources reviewed. |
| Evidence | Primary source, independently corroborated · 2 source(s) |
| Last verified | 2026-10-25 |
Parties
- Gulf Pharmaceutical Industries (Julphar) (United Arab Emirates): licensee, manufacturer
- Dong-A ST (South Korea): licensor
Key terms
- Interest: exclusive licence; Exclusivity: exclusive; Territorial scope: MENA region (no country list stated)
Sources
- Julphar Announces Strategic Licensing Partnership with Dong A ST to Launch Innovative Biotechnology Product in MENA, Julphar (Gulf Pharmaceutical Industries), 2025-03-10
- Middle East Pharmaceutical Market report – mention of the Julphar / Dong-A ST licensing partnership, Grand View Research, 2025-09-18
Part of The Meridian’s Africa IP database. Counts, market breakdowns and rankings are derived from published records only; a record counts once. Corrections: submit evidence.


